83057-0

LOINC code 83057-0 identifies "PD-L1 by clone SP142 [Presence] in Tissue by Immune stain". This term should be used to report the degree of PD-L1 (CD274) protein expression in tumor cells as determined by immune staining with anti-PD-L1 clone SP142. Patients with certain cancers, such as non small cell lung cancer (NSCLC) or urothelial carcinoma, whose tumors are positive for PD-L1 by SP142, may be eligible for anti-programmed death 1 (PD-1) receptor antibody therapy, which effectively prevents the binding of PD-L1 to PD-1. The percentage of viable tumor cells that show partial or complete PD-L1 membrane staining is reported using [LOINC: 83053-9]. If at least 50% of tumor cells or at least 10% of inflammatory cells stain positive with SP142, the tumor is considered to have high PD-L1 expression, and if 1 to 50% of tumor cells and 1 to 10% of inflammatory cells stain positive, the tumor has low expression. If <1% of both tumor and inflammatory cells stain positive, the tumor is considered to have no PD-L1 expression. This term was created for, but is not limited in use to, the Ventana PD-L1 (SP142) assay, which, as of November 2016, is FDA-approved as a companion diagnostic to assess whether patients with certain cancers are eligible for atezolizumab therapy.

This code measures Programmed cell death ligand 1 by clone SP142 in Tiss. It belongs to the PATH class in the LOINC classification.

LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.